Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jonas Bäckström"'
Autor:
Peter Juhasz, Björn Glinghammar, Jonas Bäckström, Shunghuang Wang, Ina Schuppe-Koistinen, Lars I. Nord, Maritha Marcusson-Ståhl, Johan Kolmert, Raji Balasubramanian, Steve Martin, Chenhui Zeng, Ulf Andersson, Kerstin Nilsson, Karin Cederbrant, Mira Hannula, Johan Lindberg
Publikováno v:
Biomarkers. 14:572-586
Ximelagatran was developed for the prevention and treatment of thromboembolic conditions. However, in long-term clinical trials with ximelagatran, the liver injury marker, alanine aminotransferase (ALT) increased in some patients. Analysis of plasma
Autor:
Guy L. Reed, Vinay Bhal, Lisa K. Jennings, Henry E. Speich, Jonas Bäckström, Kourtney H. Houser, Alex T. Caughran, Aiilyan K. Houng, Malin Enerbäck, Lindsey T. Lands
Publikováno v:
Journal of cardiovascular pharmacology. 63(6)
P2Y(12) receptor antagonism inhibits platelet aggregation by preventing adenosine diphosphate (ADP)-mediated amplification of activation pathways downstream of primary agonists, such as thrombin and collagen. However, the role of ADP signaling in mai
Autor:
Ulrika Logren, Henrik Svennberg, Martin Ahnoff, Kristina Dunér, Jonas Bäckström, Niklas Magnell
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 852(1-2)
An analytical method was developed for the determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the two intermediate metabolites, OH-melagatran and ethyl-melagatran in human plasma. Extraction of pla